CYCC
Price
$0.23
Change
+$0.01 (+4.55%)
Updated
Apr 17 closing price
Capitalization
46.88M
ORMP
Price
$2.15
Change
-$0.05 (-2.27%)
Updated
Apr 17 closing price
Capitalization
87.83M
40 days until earnings call
Ad is loading...

CYCC vs ORMP

Header iconCYCC vs ORMP Comparison
Open Charts CYCC vs ORMPBanner chart's image
Cyclacel Pharmaceuticals
Price$0.23
Change+$0.01 (+4.55%)
Volume$56.98K
Capitalization46.88M
Oramed Pharmaceuticals
Price$2.15
Change-$0.05 (-2.27%)
Volume$35.17K
Capitalization87.83M
CYCC vs ORMP Comparison Chart
Loading...
CYCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYCC vs. ORMP commentary
Apr 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYCC is a Hold and ORMP is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 18, 2025
Stock price -- (CYCC: $0.23 vs. ORMP: $2.15)
Brand notoriety: CYCC and ORMP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYCC: 22% vs. ORMP: 12%
Market capitalization -- CYCC: $46.88M vs. ORMP: $87.83M
CYCC [@Biotechnology] is valued at $46.88M. ORMP’s [@Biotechnology] market capitalization is $87.83M. The market cap for tickers in the [@Biotechnology] industry ranges from $282.79B to $0. The average market capitalization across the [@Biotechnology] industry is $2.08B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYCC’s FA Score shows that 1 FA rating(s) are green whileORMP’s FA Score has 0 green FA rating(s).

  • CYCC’s FA Score: 1 green, 4 red.
  • ORMP’s FA Score: 0 green, 5 red.
According to our system of comparison, both CYCC and ORMP are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYCC’s TA Score shows that 5 TA indicator(s) are bullish while ORMP’s TA Score has 3 bullish TA indicator(s).

  • CYCC’s TA Score: 5 bullish, 3 bearish.
  • ORMP’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, CYCC is a better buy in the short-term than ORMP.

Price Growth

CYCC (@Biotechnology) experienced а +1.85% price change this week, while ORMP (@Biotechnology) price change was +0.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.02%. For the same industry, the average monthly price growth was -13.21%, and the average quarterly price growth was -24.46%.

Reported Earning Dates

CYCC is expected to report earnings on Mar 27, 2024.

ORMP is expected to report earnings on Aug 13, 2025.

Industries' Descriptions

@Biotechnology (+7.02% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ORMP($87.8M) has a higher market cap than CYCC($46.9M). ORMP YTD gains are higher at: -11.157 vs. CYCC (-39.867). ORMP has higher annual earnings (EBITDA): 9.44M vs. CYCC (-15.47M). ORMP has more cash in the bank: 142M vs. CYCC (2.98M). CYCC has less debt than ORMP: CYCC (0) vs ORMP (429K). CYCC has higher revenues than ORMP: CYCC (74K) vs ORMP (0).
CYCCORMPCYCC / ORMP
Capitalization46.9M87.8M53%
EBITDA-15.47M9.44M-164%
Gain YTD-39.867-11.157357%
P/E RatioN/A20.91-
Revenue74K0-
Total Cash2.98M142M2%
Total Debt0429K-
FUNDAMENTALS RATINGS
CYCC vs ORMP: Fundamental Ratings
CYCC
ORMP
OUTLOOK RATING
1..100
6061
VALUATION
overvalued / fair valued / undervalued
1..100
30
Undervalued
68
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9980
PRICE GROWTH RATING
1..100
9572
P/E GROWTH RATING
1..100
10042
SEASONALITY SCORE
1..100
n/a13

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CYCC's Valuation (30) in the Biotechnology industry is somewhat better than the same rating for ORMP (68) in the Pharmaceuticals Other industry. This means that CYCC’s stock grew somewhat faster than ORMP’s over the last 12 months.

CYCC's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ORMP (100) in the Pharmaceuticals Other industry. This means that CYCC’s stock grew similarly to ORMP’s over the last 12 months.

ORMP's SMR Rating (80) in the Pharmaceuticals Other industry is in the same range as CYCC (99) in the Biotechnology industry. This means that ORMP’s stock grew similarly to CYCC’s over the last 12 months.

ORMP's Price Growth Rating (72) in the Pharmaceuticals Other industry is in the same range as CYCC (95) in the Biotechnology industry. This means that ORMP’s stock grew similarly to CYCC’s over the last 12 months.

ORMP's P/E Growth Rating (42) in the Pharmaceuticals Other industry is somewhat better than the same rating for CYCC (100) in the Biotechnology industry. This means that ORMP’s stock grew somewhat faster than CYCC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYCCORMP
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
88%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
78%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 10 days ago
83%
N/A
Declines
ODDS (%)
Bearish Trend 12 days ago
89%
Bearish Trend 2 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Ad is loading...
CYCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PRLD0.810.04
+5.19%
Prelude Therapeutics
REYN23.650.55
+2.38%
Reynolds Consumer Products
DAC76.710.68
+0.89%
Danaos Corp
MAR220.411.62
+0.74%
Marriott International
MPB25.390.14
+0.55%
Mid Penn Bancorp

CYCC and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYCC has been loosely correlated with CARA. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if CYCC jumps, then CARA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYCC
1D Price
Change %
CYCC100%
+4.48%
CARA - CYCC
61%
Loosely correlated
N/A
CKPT - CYCC
52%
Loosely correlated
N/A
MIRM - CYCC
36%
Loosely correlated
+0.90%
ORMP - CYCC
30%
Poorly correlated
-2.27%
IMMP - CYCC
27%
Poorly correlated
+6.21%
More

ORMP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORMP has been loosely correlated with BTAI. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ORMP jumps, then BTAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORMP
1D Price
Change %
ORMP100%
-2.27%
BTAI - ORMP
44%
Loosely correlated
-4.40%
INO - ORMP
44%
Loosely correlated
+1.16%
MBIO - ORMP
44%
Loosely correlated
-0.75%
VERV - ORMP
44%
Loosely correlated
+1.77%
ZNTL - ORMP
43%
Loosely correlated
+2.38%
More